Prognostic biomarkers for patients with advanced renal cell carcinoma

Tyrosine kinase inhibitors with activity against vascular endothelial growth factor receptor 2 are now standard treatment for the majority of patients with advanced renal cell carcinoma.09/06/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news